←
Eduardo Marban, MD, PhD1,378 posts
Eduardo Marban, MD, PhD avatar

Eduardo Marban, MD, PhD

@MarbanLab

Dr. Eduardo Marban | Executive Director, Smidt Heart Institute @CedarsSinai Views are my own, not institutional policy!

◷ Joined May 2021▧ 411 Photos and videos
Eduardo Marban, MD, PhD avatar
Eduardo Marban, MD, PhD@MarbanLab·Nov 9

Rigorous studies of deramiocel’s efficacy in @Duchenne @cardiomyopathy. Strong evidence of disease-modifying bioactivity in advanced @DMD, especially in the prespecified subgroup of HOPE-3 subjects with cardiomyopathy at baseline. Progression totally halted over one year of follow-up, with a trend towards net improvement— contrary to the relentless progression of dysfunction and scar in the placebo group. Congrats Jon Soslow, Chet Vila and team!

This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible. Read the press release: bit.ly/4BMIYM5 #AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR

Post attachment
Eduardo Marban, MD, PhD avatar
Eduardo Marban, MD, PhD@MarbanLab·Nov 4

.@FDA has proclaimed their innovative, proactive approach to rare diseases, but will they deliver? By any measure, #deramiocel exceeds the typical burden of evidence for efficacy and safety in a rare disease, with no less than 5 positive clinical trials. But FDA has yet to approve this novel cell therapy for #Duchenne muscular dystrophy. Meanwhile, boys and young men with advanced #DMD—precisely those who stand to benefit most from deramiocel—are awaiting this potentially transformational therapy. It’s time for FDA to do more than talk about rare diseases! The 28 authors of our recent @TheLancet HOPE-3 paper wrote the attached letter making these points to @FDA-- have a look! Link for full letter lnkd.in/p/gptcbDKX

Post attachmentPost attachmentPost attachmentPost attachment
Elijah Stacy avatar
⟳ Eduardo Marban, MD, PhD retweeted
Elijah Stacy@Elijahjstacy·Nov 3

Dr. Craig McDonald and the other 28 physician-scientists/investigators in HOPE-3 have spoken! @FDA trust the expert DMD physicians who work with us patients the most. Approve Deramiocel! $CAPR Read the full letter on Dr. McDonald’s LinkedIn by clicking this link: lnkd.in/p/gBMSkKUS

Post attachmentPost attachmentPost attachmentPost attachment
Eduardo Marban, MD, PhD avatar
Eduardo Marban, MD, PhD@MarbanLab·Sep 30

Late Breaking clinical trial #HOPE-3 OLE shows striking benefits of #deramiocel sustained over two years of therapy, and 76% slowing of #Duchenne myopathy progression in those who crossed over from placebo to deramiocel after one year. Work of ace #DMD trialist Craig McDonald highlighted at the @WorldMuscleSoc meeting in Hiroshima. Trial sponsored by @Capricor based on intellectual property from my team at Cedars-Sinai.

Post attachment
Eduardo Marban, MD, PhD avatar
Eduardo Marban, MD, PhD@MarbanLab·Sep 23

Enjoyed my visit to @dgsomucla and the opportunity to discuss #exomers for #scleroderma, #Duchenne and #arrythmogenic #cardiomyopathy @TheIbrahimLab @AleCiulloPhD @rrogerslab @EugenioCingolan @soussi_salwa @XMichaelJonesMD

Delighted to have @MarbanLab for an inspiring talk on translating cardiosphere-derived cell biology into RNA therapeutics. Fascinating insights into extracellular vesicles, Y RNA, macrophage reprogramming, tissue repair, and TY1; from discovery to clinical translation. #UCLA

Post attachmentPost attachmentPost attachmentPost attachment